EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC-ND 4.0

Pre‐Therapeutic UGT1A1 Genotyping in Breast Cancer Patients Receiving Sacituzumab Govitecan to Improve Safety: A Meta‐Analysis and Recommendation

Tessa Goedhart iD, Henk-Jan Guchelaar iD

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70462 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Tessa Goedhart und 1 weiteren Autor:innen. Beteiligte Einrichtung: Leiden University, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Breast Neoplasms, Camptothecin, Glucuronosyltransferase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pre‐therapeutic UGT1A1 genotyping is increasingly performed in patients receiving irinotecan, as its active metabolite SN‐38 is primarily cleared through UGT1A1 ‐mediated glucuronidation. Patients with the UGT1A1*28/*28 genotype exhibit reduced UGT1A1 activity, leading to increased SN‐38 exposure and a higher risk of adverse events such as neutropenia and diarrhea. Although sacituzumab govitecan contains the same active metabolite as irinotecan, routine UGT1A1 genotyping prior to treatment with this drug is not yet standard practice and is not included in its product information. The aim of this study was to assess whether pre‐therapeutic UGT1A1 genotyping may also benefit patients with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative and triple‐negative breast cancer who are treated with sacituzumab govitecan. A literature search was conducted to identify relevant studies assessing the impact of UGT1A1 genotyping on the safety and efficacy of sacituzumab govitecan treatment. A meta‐analysis was performed on selected studies. Additionally, a pharmacological analysis was performed using public data comparing SN‐38 levels in patients treated with sacituzumab govitecan to those receiving irinotecan. The meta‐analysis shows that grade ≥ 3 adverse events, including neutropenia, febrile neutropenia, and diarrhea, occurred more frequently in patients with the *28/*28 genotype. Furthermore, a statistically significant increased risk was found for developing grade ≥ 3 diarrhea or febrile neutropenia in this group. Although the meta‐analysis was underpowered due to small sample sizes, the pharmacological analysis demonstrated higher SN‐38 levels in patients treated with sacituzumab govitecan, supporting the rationale for UGT1A1 genotyping in this context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedBreast NeoplasmsCamptothecinGlucuronosyltransferaseImmunoconjugatesFemaleHumansGenotypeIrinotecanTopoisomerase I InhibitorsUGT1A1 Enzyme

Stichwörter der Autor:innen

UGT1A1irinotecansacituzumab govitecantriple negative breast cancer

Substanzen

Antibodies, Monoclonal, HumanizedCamptothecinGlucuronosyltransferaseIrinotecanTopoisomerase I InhibitorsImmunoconjugatesUGT1A1 Enzymesacituzumab govitecan

Autor:innen und Institutionen

  • Leiden University, Leiden, the Netherlands.
  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.

ORCID-Profile: Tessa Goedhart, Henk-Jan Guchelaar

Zitieren

APA

Goedhart, T., & Guchelaar, H. J. (2026). Pre‐Therapeutic UGT1A1 Genotyping in Breast Cancer Patients Receiving Sacituzumab Govitecan to Improve Safety: A Meta‐Analysis and Recommendation. Clinical and Translational Science. https://doi.org/10.1111/cts.70462

Vancouver

Goedhart T, Guchelaar HJ. Pre‐Therapeutic UGT1A1 Genotyping in Breast Cancer Patients Receiving Sacituzumab Govitecan to Improve Safety: A Meta‐Analysis and Recommendation. Clinical and Translational Science. 2026. doi:10.1111/cts.70462

BibTeX
@article{Goedhart2026,
  author = {Goedhart, Tessa and Guchelaar, Henk-Jan},
  title = {Pre‐Therapeutic UGT1A1 Genotyping in Breast Cancer Patients Receiving Sacituzumab Govitecan to Improve Safety: A Meta‐Analysis and Recommendation},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70462}
}
Kostenlos starten →